← Actinium Pharmaceuticals, Inc. (ATNM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Actinium Pharmaceuticals, Inc. (ATNM)
Pharmaceutical Preparations · market cap $37M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Actinium Pharmaceuticals (ATNM) is a clinical-stage radiopharmaceutical company with a $29M market cap and 25 employees, trading at ~$0.92/share. Its lead asset, Iomab-B, is in Phase 3 development for Acute Myeloid Leukemia (AML), and the company holds $42.1M in cash — more than its market cap — implying the pipeline is being valued at a discount to net cash. The next formal catalyst is an earnings release on 2026-08-14.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Iomab-B | Phase 3 | Acute Myeloid Leukemia |
| Cytarabine (Phase 1 only) | Phase 2 | AML |
Price & technical context
3-month
+17.3%
6-month
+16.2%
12-month
-28.1%
52-wk range
$0.75–$1.69
vs 50-day MA
+10.7%
vs 200-day MA
+0.6%
Realized vol
67.7%
Max drawdown
-61.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ATNM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.